Literature DB >> 11815359

Intravitreal triamcinolone acetonide for macular oedema due to central retinal vein occlusion.

Paul B Greenberg, Adam Martidis, Adam H Rogers, Jay S Duker, Elias Reichel.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11815359      PMCID: PMC1771005          DOI: 10.1136/bjo.86.2.247

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


× No keyword cloud information.
  5 in total

1.  Intravitreal triamcinolone acetonide in exudative age-related macular degeneration.

Authors:  R P Danis; T A Ciulla; L M Pratt; W Anliker
Journal:  Retina       Date:  2000       Impact factor: 4.256

2.  Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation.

Authors:  C A Wilson; B A Berkowitz; Y Sato; N Ando; J T Handa; E de Juan
Journal:  Arch Ophthalmol       Date:  1992-08

3.  Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study.

Authors:  R J Antcliff; D J Spalton; M R Stanford; E M Graham; T J ffytche; J Marshall
Journal:  Ophthalmology       Date:  2001-04       Impact factor: 12.079

4.  Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report.

Authors: 
Journal:  Ophthalmology       Date:  1995-10       Impact factor: 12.079

5.  Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide.

Authors:  Y Tano; D Chandler; R Machemer
Journal:  Am J Ophthalmol       Date:  1980-12       Impact factor: 5.258

  5 in total
  61 in total

1.  Intraocular pressure after intravitreal injection of triamcinolone acetonide.

Authors:  J B Jonas; I Kreissig; R Degenring
Journal:  Br J Ophthalmol       Date:  2003-01       Impact factor: 4.638

Review 2.  The management of retinal vein occlusion: is interventional ophthalmology the way forward?

Authors:  H Shahid; P Hossain; W M Amoaku
Journal:  Br J Ophthalmol       Date:  2006-05       Impact factor: 4.638

3.  The effect of arteriovenous sheathotomy on cystoid macular oedema secondary to branch retinal vein occlusion.

Authors:  M T Cahill; P K Kaiser; J E Sears; S Fekrat
Journal:  Br J Ophthalmol       Date:  2003-11       Impact factor: 4.638

4.  Intravitreal triamcinolone acetonide for ischaemic macular oedema caused by branch retinal vein occlusion.

Authors:  S D M Chen; J Lochhead; C K Patel; P Frith
Journal:  Br J Ophthalmol       Date:  2004-01       Impact factor: 4.638

5.  Pseudo-endophthalmitis after intravitreal injection of triamcinolone.

Authors:  F K P Sutter; M C Gillies
Journal:  Br J Ophthalmol       Date:  2003-08       Impact factor: 4.638

Review 6.  Pseudohypopyon after intravitreal triamcinolone injection for the treatment of pseudophakic cystoid macular oedema.

Authors:  S D M Chen; J Lochhead; B McDonald; C K Patel
Journal:  Br J Ophthalmol       Date:  2004-06       Impact factor: 4.638

7.  Sequential treatment of central retinal vein occlusion with intravitreal tissue plasminogen activator and intravitreal triamcinolone.

Authors:  J M Lahey; J J Kearney; M C Cheung
Journal:  Br J Ophthalmol       Date:  2004-08       Impact factor: 4.638

8.  Intravitreal triamcinolone for the treatment of refractory diabetic macular oedema with hard exudates: an optical coherence tomography study.

Authors:  A P Ciardella; J Klancnik; W Schiff; G Barile; K Langton; S Chang
Journal:  Br J Ophthalmol       Date:  2004-09       Impact factor: 4.638

9.  Intravitreal triamcinolone acetonide for florid proliferative diabetic retinopathy.

Authors:  Francesco Bandello; Derri Roman Pognuz; Angelo Pirracchio; Antonio Polito
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-04-03       Impact factor: 3.117

10.  Factors influencing visual acuity after intravitreal triamcinolone acetonide as treatment of exudative age related macular degeneration.

Authors:  J B Jonas; I Kreissig; R F Degenring
Journal:  Br J Ophthalmol       Date:  2004-12       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.